Few diagnostics start-ups are bona fidebusiness successes, and that has put a damper on venture capital interest in the field. But it hasn't stopped some hearty pioneers from making bets on diagnostic tests. Perhaps they are attracted by the shorter time-to-market for diagnostics than pharmaceuticals or biotechnology, or the promise of a technology that meets an unmet need. Then again, diagnostics IPOs seem to garner attractive step-up multiples; a 5.2 pre-money average in 1997 and post-money average of 8.4, better than pharmaceutical companies' post-IPO multiple of 3.14 and 5.0 for device IPOs (including financings through August of ‘97), regardless of their eventual business success.(Step-up multiples calculate the increase in value from one financing round to the next by dividing pre-and post-money IPO valuations by total private investment.)
If investor interest is low, it isn't because the world has all the diagnostic tests it needs. And it isn't...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?